🟠 Moderate Evidence
Buruli ulcer, a neglected tropical disease caused by Mycobacterium ulcerans, remains a significant public health challenge across sub-Saharan Africa, with diagnostic delays and limited treatment infrastructure perpetuating disability and social stigma. A comprehensive analysis published in Nature Reviews Disease Primers (June 2026) examines the tension between advancing diagnostic and therapeutic innovations and the pragmatic realities of delivering care in resource-limited settings across the continent.
Key takeaways
- Buruli ulcer diagnostic delays remain a critical barrier to early treatment and functional outcomes in affected regions
- Novel molecular diagnostic tools and oral antimicrobial regimens show promise but face implementation challenges in decentralized health systems
- Integration of community health workers and traditional healers into surveillance and referral networks may improve case detection
- Economic constraints and stigma continue to limit access to standardized wound care and surgical management
A disease of poverty and isolation
Buruli ulcer predominantly affects impoverished populations in West and Central Africa, with the disease burden concentrated in countries with fragmented health infrastructure. According to the World Health Organization, case notification patterns reveal that diagnostic delay—often exceeding 12 months from symptom onset—remains endemic in affected communities, driving progression from small nodules to extensive ulceration with contracture and permanent disability.
The disease’s association with poverty, limited access to primary healthcare, and the migration of patients to traditional healers before seeking biomedical care compounds early detection challenges. The Nature Reviews analysis documents that social stigma surrounding the ulcers—which resemble leprosy and are often attributed to supernatural causes—creates additional barriers to health-seeking behaviour and treatment adherence across the region.
Buruli ulcer’s silent spread: delays and disparities across sub-Saharan Africa
Median diagnostic delay (months) and health system access barriers by region, illustrative analysis based on WHO surveillance data
Source: WHO / Nature Reviews Disease Primers (2026) | Georgian Medical Journal News
Diagnostic innovation meets implementation reality
Recent advances in molecular diagnostics—particularly PCR-based detection of M. ulcerans DNA—have dramatically improved sensitivity and specificity compared to traditional histopathology and culture methods. However, as documented in Nature Reviews Disease Primers, the deployment of these technologies in sub-Saharan Africa confronts persistent obstacles: lack of laboratory infrastructure, shortage of trained technicians, and the concentration of diagnostic capacity in tertiary urban facilities far from affected communities.
The review emphasizes that point-of-care diagnostics—including lateral flow assays and rapid immunochromatographic tests—represent a crucial frontier for decentralized case detection. Yet evidence from pilot programmes in Ghana and Benin shows that even when diagnostics are available at health posts, the absence of standardized protocols, quality assurance mechanisms, and reliable supply chains undermines their utility. Pragmatic implementation requires not only technological innovation but also investment in health worker training, supply chain management, and integration with existing surveillance systems at the district level.
Visit Clinical Updates for more on diagnostic advances in tropical medicine.
Treatment options: between efficacy and accessibility
The introduction of oral antimicrobial combination therapy—principally rifampicin with either clarithromycin or fluoroquinolones—has transformed Buruli ulcer treatment from exclusively surgical excision to a multimodal approach combining antimicrobials with surgery where needed. The Nature Reviews analysis notes that WHO-recommended oral regimens have demonstrated efficacy rates above 90% in controlled settings, with the added advantage of reduced hospitalisation and lower societal costs compared to extensive surgical management.
Nevertheless, pragmatic barriers persist: antimicrobial availability remains inconsistent across sub-Saharan Africa, with procurement delays, stock-outs, and variable quality of generic formulations documented in multiple countries. Patient adherence to 12-week oral therapy is complicated by poverty, food insecurity, and the need to travel repeatedly to health facilities for monitoring. Importantly, when early surgical debridement is required—particularly in cases with significant osteomyelitis—the absence of surgical expertise in district hospitals forces referrals to tertiary centres, creating delays that allow bacterial dissemination and worsen functional outcomes.
Early detection combined with oral antimicrobial therapy can prevent severe disability in up to 90% of cases, yet diagnostic delays exceeding 12 months remain the norm across West and Central Africa, driving progression to advanced ulceration with permanent contracture and loss of function.
— Nature Reviews Disease Primers (2026)
Integrating innovation with community-based surveillance
The most promising pathway forward, according to Nature Reviews Disease Primers, lies in strengthening community-embedded case detection through decentralized health systems. This approach recognizes that innovation in diagnostics and therapeutics must be coupled with pragmatic strengthening of primary health care infrastructure, health worker capacity, and community engagement.
Pilot programmes in Nigeria, Uganda, and Cameroon have demonstrated that training community health workers to screen for suspicious skin lesions, conduct rapid diagnostics, and refer positive cases to treatment centres significantly reduces diagnostic delays. Integration of traditional healers into surveillance networks—positioning them as community sentries rather than competitors—has also improved case referral in settings where cultural trust in traditional medicine remains high.
The economic case for investment is compelling: early diagnosis and oral therapy cost approximately USD 50–150 per patient versus USD 500–2,000 for surgical management of advanced disease. Yet sustained funding for decentralized diagnostic capacity, continuous health worker training, and community engagement remains fragile, dependent on cyclical donor support and competing health priorities. Health Policy initiatives focused on domesticating financing for neglected tropical disease programmes will be critical to scaling these interventions.
What this means
Frequently asked questions
What causes Buruli ulcer and how is it transmitted?
Buruli ulcer is caused by Mycobacterium ulcerans, an environmental mycobacterium found in water and soil. Transmission to humans occurs through direct contact with contaminated water or soil, particularly in wet environments such as marshes and slow-moving water bodies. The exact mechanism of infection remains partially understood, though epidemiological data suggest exposure during agricultural or domestic water contact.
Why are diagnostic delays so common in affected regions?
Diagnostic delays result from multiple factors: limited access to primary healthcare, concentration of diagnostic expertise in distant urban centres, patient consultation of traditional healers before biomedical facilities, and social stigma that discourages health-seeking behaviour. In many affected communities, early skin lesions are misattributed to supernatural causes or treated locally, delaying presentation to health systems until advanced ulceration has occurred.
Can oral antimicrobial therapy alone cure Buruli ulcer?
According to Nature Reviews Disease Primers, oral antimicrobial therapy is highly effective for early-stage disease but works best when combined with surgical debridement in cases with significant tissue damage or osteomyelitis. The WHO-recommended approach is multimodal: 12 weeks of oral antimicrobials (rifampicin plus clarithromycin or fluoroquinolone) combined with targeted surgery when needed, achieving cure rates above 90% with minimal disability.
The path forward for Buruli ulcer control in Africa requires neither abandoning innovation nor accepting present limitations as permanent. Instead, success depends on embedding diagnostics and therapeutics within strengthened health systems that prioritise accessibility, quality, and community participation. Investment in health worker capacity, reliable supply chains, and integration of community-based surveillance with facility-based treatment represents a pragmatic strategy that honours both scientific evidence and the economic and social realities of resource-limited settings. As global health priorities shift, sustained commitment to neglected tropical diseases—particularly those affecting Africa’s poorest populations—remains essential to realizing universal health coverage and health equity.
Source: Buruli ulcer in Africa: between innovation and pragmatism, Nature Reviews Disease Primers (June 2026)
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
